Stock Code: 300381 stock abbreviation: Guangdong Vtr Bio-Tech Co.Ltd(300381)
Bond Code: 123018 bond abbreviation: profit convertible bond Announcement No.: 2022-016 Guangdong Vtr Bio-Tech Co.Ltd(300381)
Announcement of resolutions of the 10th meeting of the 7th board of supervisors
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
The 10th meeting of the 7th board of supervisors of Guangdong Vtr Bio-Tech Co.Ltd(300381) (hereinafter referred to as “the company”) was held by on-site voting in the conference room on the third floor of the company on February 18, 2022. The notice of the meeting was sent to all supervisors of the company by SMS and email on February 7, 2022. Three supervisors shall attend the meeting and three supervisors actually attend the meeting. The convening of the meeting shall comply with the provisions of the company law of the people’s Republic of China, the articles of association and the rules of procedure of the board of supervisors. The meeting was presided over by Ms. Feng Dan, chairman of the board of supervisors. The following proposals were considered and adopted by voting:
1、 The proposal on adjusting the grant price of the restricted stock incentive plan in 2021 was deliberated and adopted. The proposal on the profit distribution plan of the company in 2020 was deliberated and adopted at the fourth meeting of the seventh board of directors held on April 23, 2021 and the 2020 annual general meeting of shareholders held on May 17, 2021, Based on 490058748 shares of the company’s total share capital as of December 31, 2020, a cash dividend of RMB 0.70 (including tax) will be distributed to all shareholders for every 10 shares. No bonus shares will be given in this profit distribution, no accumulation fund will be converted into share capital, and the remaining undistributed profits will be carried forward to the next year. The annual equity distribution in 2020 has been implemented.
In view of the distribution of stock dividends and other matters of the company, according to the relevant provisions of the company’s 2021 restricted stock incentive plan and the authorization of the first extraordinary general meeting of shareholders in 2021, the board of directors of the company agreed to adjust the first and reserved grant prices of class II restricted shares in the 2021 restricted stock incentive plan from 5.06 yuan / share to 4.99 yuan / share.
In addition to the above adjustments, other contents of the incentive plan implemented this time are consistent with the incentive plan deliberated and approved at the first extraordinary general meeting of shareholders in 2021.
For details, please refer to the company’s announcement on cninfo (www.cn. Info. Com. CN.) on the same day Announcement on adjusting the grant price of restricted stock incentive plan in 2021.
Voting results: 3 in favor, 0 against and 0 abstention.
2、 The proposal on granting reserved restricted shares to incentive objects was deliberated and adopted.
In accordance with the relevant provisions of the measures for the administration of equity incentive of listed companies, the Listing Rules of gem shares of Shenzhen Stock Exchange and the company’s restricted stock incentive plan in 2021, as well as the authorization of the company’s first extraordinary general meeting in 2021, The company believes that the reserved grant conditions of class II Restricted Shares specified in the 2021 restricted stock incentive plan have been met, and agrees to determine February 18, 2022 as the reserved grant date to grant 800000 reserved class II restricted shares to 22 incentive objects who meet the reserved grant conditions at the grant price of 4.99 yuan / share.
For details, please refer to the company’s announcement on cninfo (www.cn. Info. Com. CN.) on the same day Announcement on granting reserved restricted shares to incentive objects
Voting results: 3 in favor, 0 against and 0 abstention.
3、 The proposal on using some idle raised funds to temporarily supplement working capital was deliberated and adopted. In order to improve the use efficiency of raised funds, reduce financial costs and alleviate the demand pressure of working capital, the company plans to use some idle raised funds with a total amount of no more than 90 million yuan to temporarily supplement working capital. The service life of the above idle raised funds used to temporarily supplement working capital shall not exceed 12 months from the date of deliberation and approval by the board of directors, The raised funds shall be returned to the special account for raised funds of the company in batches according to the use progress of the raised funds.
The board of supervisors believes that the company temporarily replenishes some idle raised funds to meet the needs of the company’s production and operation for working funds, which is conducive to improving the use efficiency of idle raised funds and will not affect the normal progress of raised funds projects, which is in line with the company law The regulatory guidelines for listed companies No. 2 – regulatory requirements for the management and use of raised funds by listed companies, the guidelines for the standardized operation of companies listed on the gem of Shenzhen Stock Exchange, the articles of association and other relevant laws, regulations and normative documents have fulfilled the necessary review procedures, which is in line with the interests of the company and all shareholders. Therefore, it is agreed that the company will use some idle raised funds to supplement working capital temporarily.
Voting results: 0 votes, 3 abstentions.
It is hereby announced.
Guangdong Vtr Bio-Tech Co.Ltd(300381) board of supervisors
February 19, 2022
